

TABLE S1. Antidepressant medication at baseline (all participants)

Antidepressant class	No prior depression, but with antidepressant treatment at baseline* <i>n=34</i>						Prior depression and with antidepressant treatment at baseline <i>n=163</i>					
	SSRIs	N	%	Other antidepressants	N	%	SSRIs	N	%	Other antidepressants	N	%
Antidepressant agents	citalopram	02	10	SNRI duloxetine	00	00	citalopram	23	20	SNRI duloxetine	08	17
	escitalopram	02	10	SNRI venlafaxine	03	21	escitalopram	29	25	SNRI venlafaxine	15	32
	sertraline	09	45	NDRI bupropion	01	07	sertraline	39	34	NDRI bupropion	11	23
	paroxetine	05	25	NaSSa mirtazapine	01	07	paroxetine	12	10	NaSSa mirtazapine	08	17
	fluoxetine	02	10	Trazodone	09	64	fluoxetine	13	11	Trazodone	03	06
				TCA amitriptyline	00	00				TCA amitriptyline	00	00
				TCA nortriptyline	00	00				TCA nortriptyline	01	02
				Tetracyclic antidepressants	00	00				Tetracyclic antidepressants	00	00
				MAO-inhibitor	00	00				MAO-inhibitor	01	02
				tranylcypromine						tranylcypromine		
Treatment duration (days)	SSRIs	Other antidepressants					SSRIs	Other antidepressants				
	Mean	1475				1484		2481				1703
	SD	1182				1747		2718				1628
	Minimum	238				166		04				269
	Maximum	4583				6126		16051				9422

* Antidepressant medication due to an indication other than depression.

SSRI: selective serotonin reuptake inhibitors, SNRI: serotonin-norepinephrine reuptake inhibitor, NDRI: norepinephrine-dopamine reuptake inhibitor, NaSSa: Noradrenergic and specific serotonergic antidepressant, TCA: tricyclic antidepressant, MAO-inhibitor: monoamine oxidase inhibitor.

FIGURE S1.





FIGURE S2.

A



B





FIGURE S3.

A Mean CSF amyloid- β concentrations of MCI patients with pathological amyloid- β levels ($<192\text{pg/ml}$)



B Mean CSF amyloid- β concentrations of MCI patients with non-pathological amyloid- β levels ($\geq 192\text{pg/ml}$)

